FDA Approves Selpercatinib for Lung & Thyroid Cancers with RET Mutations or Fusions
On May 8, 2020, the U.S. Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for the following indications:
Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC);
Adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy;
Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
In Person Meeting & NetworkingMay 6, 2026 at 8:00 AM EDT560 King Street, Charleston, SC, USAHyatt Place + Hyatt House Charleston - Historic District, Charleston
In Person Conference & ConventionMay 13, 2026 at 5:30 PM HST6600 Kalanianaʻole Highway suite 110, Honolulu, HI, USARoy's Restaurants – Hawaii Kai, Honolulu
In Person Conference & ConventionMay 20, 2026 at 5:30 PM MDT222 South 22nd Street, Laramie, WY, USAUniversity of Wyoming – Rochelle Gateway Center, Laramie
